In this interview, Chris Roberts of Aventa Genomics highlights the groundbreaking Aventa FusionPlus test, detailing its superior ability to detect gene fusions in cancer diagnostics and its pivotal role in advancing personalized oncology treatments.
Aventa™ Genomics, LLC, a clinical laboratory established as a joint venture between Arima Genomics, Inc. and Protean BioDiagnostics Inc., today announced the launch of Aventa FusionPlus, a next-generation sequencing (NGS) test for the detection of gene fusions, translocations, and rearrangements across 361 genes from formalin-fixed, paraffin embedded (FFPE) tumor tissue.